BioSpace News Archive

Certis Oncology Solutions, a clinical research organization (CRO) and precision cancer therapy company, announced today it is offering mobile COVID-19 testing services to area businesses.

Ardigen and CVC announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.

Renovion, Inc., a biopharmaceutical company on a mission to transform the lives of patients with chronic lung diseases characterized by mucus and inflammation, announced publication of results from research conducted at The University of Alabama Birmingham. The research was funded in part by the Cystic Fibrosis Foundation and was conducted at The Rowe Lab at The Gregory Fleming James Cystic Fibrosis Research Center. Res

Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential

For the first time, practitioners will be able to leverage dual-energy x-ray technology in a portable system.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased revenue estimate for Q2 and the full-year 2020.

Today during the global conference AIDS 2020: Virtual , IAVI, a scientific research organization dedicated to addressing urgent unmet health needs including HIV and tuberculosis, announced an innovative collaboration with Scripps Research and the National Institute of Allergy and Infectious Diseases (N

A new clinical trial conducted by the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG) is the first in the world to test an immune-stimulating treatment to reduce symptoms and prevent severe cases of COVID-19 and other serious respiratory infections specifically in people with cancer.

The ACIST Navvus® II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions [09-July-2020] EDEN PRAIRIE, Minn. , July 9, 2020 /PRNewswire/ -- ACIST Medical Systems, Inc., a Bracco Group Company, today announced the global launch of its ACIST Navvus II Rapid Exchange FFR MicroCatheter, the second

Biorasi , a leading global full-service contract research organization (CRO), has announced the start of the company’s third COVID-19 clinical trial for 2020. Taking place across the United States and Europe, the goal of the study is to evaluate the efficacy and safety of the candidate drug as an antiviral agent in hospitalized patients diagnosed with COVID-19 infections. “We are proud to have been selected as the CRO partner